

Melanoma Pathways: Metastatic Melanoma

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

Pathology: _____ Stage: _____

Line of Therapy: Adjuvant/Post-Op 1st Line 2nd Line 3rd Line 3rd Line+ **ECOG Performance Status:** _____ **ICD-10 Code:** _____

Biomarkers/Characteristics: (Select all that apply)

BRAF status: V600E Mutation positive V600K Mutation positive Wild Type (no mutation) Not Reported

c-kit status: Exon 11 Mutation Present Exon 9 Mutation Present No Mutation Not Reported

Stage IIIB/IIIC (Resected) | Adjuvant Therapy

Nivolumab (Opdivo)

Metastatic Disease | First and Subsequent Lines of Therapy (1st Line+) | Any BRAF Status | ECOG PS: 0-2

Pembrolizumab (Keytruda)*

Nivolumab (Opdivo) and ipilimumab (Yervoy)

Metastatic Disease | First Line of Therapy (1st Line) | BRAF Mutated† | Symptomatic Disease | ECOG PS: 0-2

Vemurafenib (Zelboraf) and cobimetinib (Cotellic)

Metastatic Disease | Second and Subsequent Lines of Therapy (2nd Line+) | BRAF Mutated† | ECOG PS: 0-2

Vemurafenib (Zelboraf) and cobimetinib (Cotellic)

Metastatic Disease | Second and Subsequent Lines of Therapy (2nd Line+) | Any BRAF Status | ECOG PS: 0-2

Ipilimumab (Yervoy)

*Administered at a dose of 2 mg/kg (up to a maximum of 200 mg)

†BRAF mutations include V600E and V600K mutations

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.



8600 West Bryn Mawr Avenue
South Tower - Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 05/22/2018 | Effective date: 08/06/2018

Appropriate.Safe.Affordable
© 2018 AIM Specialty Health
9015-0818b